Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems.
暂无分享,去创建一个
R. Snow | C. Karema | U. d’Alessandro | B. Ogutu | A. Talisuna | P. Guérin | C. Roper | E. Juma | J. Logedi | Andrew J. Nyandigisi | M. Mulenga | W. Mbacham
[1] F. Nosten,et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.
[2] P. Newton,et al. A Major Genome Region Underlying Artemisinin Resistance in Malaria , 2012, Science.
[3] Robert W. Snow,et al. Mobile Phone Text Messaging: Tool for Malaria Control in Africa , 2012, PLoS medicine.
[4] Nicholas J White,et al. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator , 2011, Malaria Journal.
[5] Robert W Snow,et al. The effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial , 2011, The Lancet.
[6] M. Laufer,et al. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data , 2011, Malaria Journal.
[7] C. Roper,et al. The Transit Phase of Migration: Circulation of Malaria and Its Multidrug-Resistant Forms in Africa , 2011, PLoS medicine.
[8] L. Decosterd,et al. Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure. , 2010, The Journal of infectious diseases.
[9] O. Stine,et al. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. , 2010, The Journal of infectious diseases.
[10] C. Roper,et al. Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. , 2010, Trends in parasitology.
[11] H. Mshinda,et al. Drug coverage in treatment of malaria and the consequences for resistance evolution - evidence from the use of sulphadoxine/pyrimethamine , 2010, Malaria Journal.
[12] Lorenz von Seidlein,et al. Artemisinin resistance: current status and scenarios for containment , 2010, Nature Reviews Microbiology.
[13] S. Groseclose,et al. Implementing integrated disease surveillance and response: Four African countries' experience, 1998–2005 , 2010, Global public health.
[14] Andrew J Tatem,et al. International population movements and regional Plasmodium falciparum malaria elimination strategies , 2010, Proceedings of the National Academy of Sciences.
[15] F. Nosten,et al. Exploring the Contribution of Candidate Genes to Artemisinin Resistance in Plasmodium falciparum , 2010, Antimicrobial Agents and Chemotherapy.
[16] R. Price,et al. In vivo parasitological measures of artemisinin susceptibility. , 2010, The Journal of infectious diseases.
[17] Margaret Chan,et al. Meeting the Demand for Results and Accountability: A Call for Action on Health Data from Eight Global Health Agencies , 2010, PLoS medicine.
[18] R. Bate,et al. Drug procurement, the Global Fund and misguided competition policies , 2009, Malaria Journal.
[19] K. Silamut,et al. Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.
[20] B. Sharp,et al. Multiple Origins and Regional Dispersal of Resistant dhps in African Plasmodium falciparum Malaria , 2009, PLoS medicine.
[21] R. Snow,et al. Malaria case-management under artemether-lumefantrine treatment policy in Uganda , 2008, Malaria Journal.
[22] Umberto D'Alessandro,et al. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance , 2008, Malaria Journal.
[23] S. Briolant,et al. Antimalarial drug use in general populations of tropical Africa , 2008, Malaria Journal.
[24] R. Snow,et al. From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia , 2008, Malaria Journal.
[25] U. d’Alessandro,et al. Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: a review of epidemiologic field evidence. , 2007, The American journal of tropical medicine and hygiene.
[26] R. Snow,et al. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya , 2007, Malaria Journal.
[27] J. Cox,et al. Detecting Epidemic Malaria, Uganda , 2007, Emerging infectious diseases.
[28] P. Ringwald,et al. Efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia , 2006, Tropical medicine & international health : TM & IH.
[29] E. Ahmed,et al. From chloroquine to artemisinin-based combination therapy: the Sudanese experience , 2006, Malaria Journal.
[30] P. Newton,et al. Manslaughter by Fake Artesunate in Asia—Will Africa Be Next? , 2006, PLoS medicine.
[31] S. Abdulla,et al. The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania , 2006, Tropical medicine & international health : TM & IH.
[32] Andrew P. Morse,et al. Malaria early warnings based on seasonal climate forecasts from multi-model ensembles , 2006, Nature.
[33] M. Peiris,et al. International Health Regulations (2005) , 2005, The Lancet.
[34] R. Snow,et al. Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study , 2005, BMJ : British Medical Journal.
[35] S. Hay,et al. The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.
[36] S. Mharakurwa. Plasmodium falciparum transmission rate and selection for drug resistance: a vexed association or a key to successful control? , 2004, International journal for parasitology.
[37] M. Mayxay,et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross‐sectional survey on the prevalence of fake antimalarials , 2004, Tropical medicine & international health : TM & IH.
[38] Joel Schwartz,et al. Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia II. Weather-based prediction systems perform comparably to early detection systems in identifying times for interventions , 2004, Malaria Journal.
[39] D. Durrheim,et al. The process of changing national malaria treatment policy: lessons from country-level studies. , 2004, Health policy and planning.
[40] B. Sharp,et al. Intercontinental Spread of Pyrimethamine-Resistant Malaria , 2004, Science.
[41] Ian M Hastings,et al. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. , 2004, The American journal of tropical medicine and hygiene.
[42] R. Snow,et al. WHO, the Global Fund, and medical malpractice in malaria treatment , 2004, The Lancet.
[43] U. d’Alessandro,et al. History, Dynamics, and Public Health Importance of Malaria Parasite Resistance , 2004, Clinical Microbiology Reviews.
[44] L. Corey,et al. The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy , 2003, Tropical medicine & international health : TM & IH.
[45] J. Kublin,et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. , 2003, The Journal of infectious diseases.
[46] E. van Marck,et al. Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[47] N. White,et al. The de novo selection of drug–resistant malaria parasites , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[48] John C. Wootton,et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum , 2002, Nature.
[49] N. White,et al. The evolution of drug-resistant malaria: the role of drug elimination half-life. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[50] J. Kublin,et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. , 2002, The Journal of infectious diseases.
[51] B. Karoumi,et al. Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience , 2001, Tropical medicine & international health : TM & IH.
[52] O. Doumbo,et al. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria , 2001, The Lancet.
[53] Ashutosh Kumar Singh,et al. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. , 2001, The Journal of infectious diseases.
[54] B. Karoumi,et al. Vitamin therapy and prevention of neural tube defects , 2001 .
[55] U. d’Alessandro,et al. Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.
[56] E. Nduati,et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. , 2000, The Journal of infectious diseases.
[57] A. Nzila,et al. Towards an Understanding of the Mechanism of Pyrimethamine-Sulfadoxine Resistance in Plasmodium falciparum: Genotyping of Dihydrofolate Reductase and Dihydropteroate Synthase of Kenyan Parasites , 2000, Antimicrobial Agents and Chemotherapy.
[58] P. Olliaro,et al. Averting a malaria disaster , 1999, The Lancet.
[59] Nájera-Morrondo Ja. Prevention and control of malaria epidemics. , 1999 .
[60] C. Plowe,et al. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. , 1997, Parasitology today.
[61] O. Doumbo,et al. Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. , 1996, The American journal of tropical medicine and hygiene.
[62] W. Wernsdorfer. Epidemiology of drug resistance in malaria. , 1994, Acta tropica.
[63] R. Steketee,et al. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. , 1993, The Journal of infectious diseases.
[64] Thomas E. Wellems,et al. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross , 1990, Nature.
[65] D. Payne. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? , 1988, Parasitology today.
[66] S. Teutsch,et al. CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM EAST AFRICA: Cultivation and Drug Sensitivity of the Tanzanian I/CDC Strain from an American Tourist , 1979, The Lancet.
[67] Andrew Weber,et al. International Health Regulations , 1971 .
[68] Clyde Df. Drug resistance of malaria parasites in Tanzania. , 1966 .
[69] T. Harinasuta,et al. Chloroquine-resistant falciparum malaria in Thailand. , 1965, Lancet.
[70] R. Snow,et al. The eff ect of mobile phone text-message reminders on Kenyan health workers ’ adherence to malaria treatment guidelines : a cluster randomised trial , 2011 .
[71] Organização Mundial de Saúde,et al. World malaria report 2011 , 2011 .
[72] J. Nájera. Prevention and control of malaria epidemics. , 1999, Parassitologia.
[73] S Lemeshow,et al. Lot quality assurance sampling: single- and double-sampling plans. , 1991, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.
[74] D. Clyde. Drug resistance of malaria parasites in Tanzania. , 1966, East African medical journal.